Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma.
Biomark Med
; 11(9): 721-731, 2017 09.
Article
em En
| MEDLINE
| ID: mdl-28658966
ABSTRACT
AIM:
Although several clinical trials demonstrated the benefits of platinum-combination adjuvant chemotherapy for stage II-IIIA lung adenocarcinoma, predictive biomarkers for the efficacy of such therapy have not yet been identified. We evaluated protein overexpression of actinin-4 as a predictive biomarker of the efficacy of adjuvant chemotherapy in resected lung adenocarcinoma. MATERIALS &METHODS:
We measured actinin-4 protein levels in patients with completely resected stage II-IIIA lung adenocarcinoma using immunohistochemistry and then retrospectively compared survival between adjuvant chemotherapy and observation groups.RESULTS:
A total of 148 eligible patients were classified into actinin-4 positive or negative cases by immunohistochemistry. In the former, patients with adjuvant chemotherapy survived significantly longer than those with observation (hazard ratio [HR] 0.307; p = 0.028). But, no significant survival benefit was noted with adjuvant chemotherapy (HR 0.926; p = 0.876) in the latter.CONCLUSION:
This marker could predict the efficacy of adjuvant chemotherapy for resected lung adenocarcinoma patients.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Actinina
/
Biomarcadores Tumorais
/
Quimioterapia Adjuvante
/
Adenocarcinoma de Pulmão
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article